Abiomed initiates online education platform for PCI

Members of CAMP PCI’s faculty take questions from physician participants during the first virtual training on 5 June 2020, broadcast live from Abiomed’s Heart Recovery Institute Abiomed has launched a virtual physician education programme, CAMP PCI (Coronary artery and myocardial protected percutaneous coronary intervention), to improve high-risk PCI patient outcomes. A press [...]

2020-06-19T11:37:19+00:00June 19th, 2020|Tags: , , |

Abiomed acquires novel ECMO developer Breethe

Abiomed (maker of the Impella heart pump) has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. A press release reports that the acquisition will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation. Such patients include those with cardiogenic [...]

2020-05-01T13:18:09+00:00May 1st, 2020|Tags: , , , |

COVID-19: Edwards pauses enrolment in mitral and tricuspid trials to allow hospitals to focus on virus

Edwards Lifesciences has temporarily paused new enrolments in its active pivotal clinical trials of its transcatheter mitral and tricuspid therapies in response to ongoing COVID-19 pandemic. A press release reports that the company is coordinating closely with the trials’ clinical investigators at the relevant hospital. It adds that the decision to resume enrolments in [...]

2020-04-06T11:21:43+00:00April 6th, 2020|Tags: , , |

FDA PMA approval for Impella 5.5 with SmartAssist

Abiomed’s Impella 5.5 with SmartAssist has received US FDA pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. The Impella 5.5 with SmartAssist system is a temporary ventricular support device intended for short term (14 days) use and indicated for the treatment of ongoing cardiogenic [...]

2019-10-01T11:08:37+00:00October 1st, 2019|Tags: , , , |

Using a “Propella” approach could aid healing in cardiogenic shock patients

Carsten Tschöpe At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Carsten Tschöpe (Charité Hospital, Berlin, Germany) outlined the use of the “Propella” approach in myocarditis patients with cardiogenic shock. He explained that the approach involves the prolonged use of an Impella heart pump (Abiomed) to provide [...]

2019-09-16T16:29:05+00:00September 16th, 2019|Tags: , , |

ESC 2019: Abiomed launches Impella SmartAssist platform

At the 2019 European Society Cardiology (ESC) congress (31 August – 4 September, Paris, France), Abiomed revealed that its Impella CP with SmartAssist technology is now commercially available in Europe. A press release reports that the system is designed to improve patient outcomes with advanced algorithms and simplified patient management. It adds that the [...]

2019-09-01T07:19:33+00:00September 1st, 2019|Tags: , , , |
Go to Top